Schering, Celera ink $365M deal
DEALS |
|||
WHO |
WITH |
WHAT |
SCOOP |
Schering |
Celera Genomics |
$365M licensing deal |
Schering has acquired Celera Genomics' cathepsin S inhibitor small molecule drug program for the treatment of autoimmune diseases. |
Pfizer |
Bayer Pharmaceuticals |
Licensing deal |
The companies have entered into an agreement granting Pfizer exclusive worldwide rights to Bayer's DGAT-1 inhibitors, a class of compounds that modify lipid metabolism. |
PTC Therapeutics |
CV Therapeutics |
Research collaboration |
The companies will work on development of orally bioavailable small molecules through the application of PTC's GEMS (Gene Expression Modulation by Small-Molecules) technology. |
U.S. Government |
Human Genome Sciences |
$165M purchase |
U.S. Government has exercised its option to purchase 20,000 treatment courses of ABthrax for the Strategic National Stockpile from HGS. |
Discovery Partners International |
Galapagos |
$5.4M purchase agreement |
All the drug discovery service operations of DPI will be transfered to Galapagos. |
Novartis |
Intercell |
$37.86M marketing deal |
Novartis has bought the rights to market IC51, a late-stage drug for the prevention of Japanese Encephalitis virus infections from Austrian biotech firm Intercell. |
PRA International |
Pharma Bio-Research |
€85M acquisition |
Pharma Bio-Research is a private early-phase clinical development company based in the Netherlands. |
Nicholas Piramal |
Pfizer |
Acquisition |
Nicholas Piramal has acquired one of Pfizer's plants in Britain. The deal includes a supply agreement until November 2011 totaling potential revenues of above $350M. |
Nutra Pharma |
ReceptoPharm |
Merger |
ReceptoPharm has signed a letter of intent to be fully acquired by Nutra Pharma, a biotech that is developing drugs for HIV and MS. |
PharmAthene |
SIGA |
Merger |
The company will operate under the "PharmAthene" name and focus on biodefense. |